GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?

Review reveals nonsteroidal anti-inflammatory drugs are effective for acute pain and 5 treatments are effective for chronic pain.

Workouts at gyms to combat muscle loss caused by GLP-1 drugs are gaining traction, but do they differ from regular strength ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

The demand for glucagon-like peptide 1 (GLP-1s) receptor agonists for overweight/obesity has created a clinical conundrum for ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving glucagon-like peptide 1 receptor agonists (GLP-1 RAs) within the context of ...